Pharmacokinetics and Pharmacodynamics — MCQs

An elderly patient presents with myocardial infarction and a severe ventricular arrhythmia. The chosen antiarrhythmic drug has a narrow therapeutic window, with a minimum toxic plasma concentration 1.5 times the minimum therapeutic plasma concentration. The drug's half-life is 6 hours. It is crucial to maintain the plasma concentration above the minimum therapeutic level to prevent lethal arrhythmia. Which of the following dosing regimens is most appropriate?

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 321: Which of the following receptors is coupled to a heterotrimeric G protein?

A. Glycine receptor
B. GABA-B receptor (Correct Answer)
C. Nicotinic acetylcholine receptor at myoneural junction
D. 5-HT3 receptor

Explanation: **Explanation:** The core concept tested here is the classification of receptors into **Ionotropic** (ligand-gated ion channels) and **Metabotropic** (G-protein coupled receptors or GPCRs). **Why GABA-B is correct:** The **GABA-B receptor** is a metabotropic receptor coupled to a **heterotrimeric G-protein** (specifically $G_i/G_o$). Activation of GABA-B leads to the inhibition of adenylyl cyclase, opening of potassium ($K^+$) channels (causing hyperpolarization), and closing of calcium ($Ca^{2+}$) channels. This mediates slow, prolonged inhibitory postsynaptic potentials. **Why the other options are incorrect:** * **Glycine receptor (Option A):** This is an **ionotropic** receptor. It is a pentameric chloride ($Cl^-$) channel that mediates fast inhibition in the spinal cord and brainstem. * **Nicotinic ACh receptor (Option C):** The Nm receptor at the neuromuscular junction is a classic **ionotropic** receptor. It is a ligand-gated cation channel ($Na^+/K^+$) that mediates rapid skeletal muscle contraction. * **5-HT3 receptor (Option D):** This is the **only ionotropic serotonin receptor**. All other serotonin receptors (5-HT1, 2, 4–7) are GPCRs. 5-HT3 is a non-selective cation channel involved in the emetic reflex. **High-Yield Clinical Pearls for NEET-PG:** * **GABA-A vs. GABA-B:** Remember "A" for **A**qua/Ion (Ionotropic - $Cl^-$ channel) and "B" for **B**oth/GPCR (Metabotropic). * **Baclofen** is a specific GABA-B agonist used clinically as a centrally acting muscle relaxant for spasticity. * **Fast vs. Slow:** Ionotropic receptors (A, C, D) act in milliseconds, while GPCRs (B) take seconds to minutes. * **Common Ionotropic Receptors (Mnemonic: "GANG"):** **G**ABA-A, **A**MPA/NMDA/Kainate, **N**icotinic, **G**lycine, and 5-HT3.

Question 322: Which of the following antimicrobial agents does not require dose reduction in patients with renal failure?

A. Rifampicin (Correct Answer)
B. Fluconazole
C. Vancomycin
D. Imipenem

Explanation: **Explanation:** The primary factor determining whether a drug requires dose adjustment in renal failure is its **route of elimination**. Drugs primarily excreted by the kidneys require dose reduction to prevent toxicity, whereas drugs metabolized by the liver or excreted via bile do not. **1. Why Rifampicin is correct:** Rifampicin is a highly lipid-soluble drug that undergoes extensive **hepatic metabolism** (deacetylation) and is primarily excreted through the **bile and feces**. Since its clearance is independent of renal function, it is safe to use in standard doses in patients with renal impairment. **2. Why the other options are incorrect:** * **Fluconazole:** Unlike other azoles (like Itraconazole), Fluconazole is primarily excreted unchanged in the urine (>80%). It requires significant dose reduction in renal failure. * **Vancomycin:** This glycopeptide is almost exclusively excreted by glomerular filtration. It is highly nephrotoxic; doses must be adjusted based on creatinine clearance or trough levels. * **Imipenem:** This carbapenem is eliminated renally. Furthermore, it is co-administered with Cilastatin to prevent its breakdown by renal dehydropeptidase-I. Accumulation in renal failure increases the risk of seizures. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Antimicrobials safe in Renal Failure:** "**D**on't **C**hange **M**edicine **L**evels" — **D**oxycycline, **C**eftriaxone/Cefoperazone, **M**acrolides (Erythromycin/Azithromycin), **L**inezolid/Lincosamides (Clindamycin). * **Rifampicin** is a potent **Inducer** of Cytochrome P450 enzymes, leading to numerous drug interactions (e.g., reducing the efficacy of OCPs and Warfarin). * **Doxycycline** is the tetracycline of choice in renal failure because it is excreted via the gut.

Question 323: Which of the following drugs is deposited in the muscles?

A. Verapamil
B. Digoxin (Correct Answer)
C. Adenosine
D. Phenytoin

Explanation: **Explanation:** The correct answer is **Digoxin**. This question tests the concept of **Volume of Distribution ($V_d$)** and tissue-specific binding [1]. **1. Why Digoxin is Correct:** Digoxin has an exceptionally large volume of distribution (~5–7 L/kg) because it is extensively sequestered in peripheral tissues, specifically **skeletal muscle** and the heart [1]. It binds to the Na+/K+-ATPase pump in these tissues [1],[3]. Because skeletal muscle represents a large percentage of total body mass, it serves as the primary reservoir for Digoxin [1]. * **Clinical Correlation:** In obese patients, Digoxin dosage should be calculated based on **Lean Body Weight (LBW)** rather than total body weight, as Digoxin does not distribute into adipose tissue. **2. Why the Other Options are Incorrect:** * **Verapamil:** While it has a large $V_d$, it does not show the characteristic high-affinity sequestration in skeletal muscle that Digoxin does. It is primarily metabolized by the liver. * **Adenosine:** It has an extremely short half-life (<10 seconds) because it is rapidly taken up by erythrocytes and endothelial cells and metabolized. It does not have time to deposit in muscles. * **Phenytoin:** It is highly protein-bound (mainly to albumin) and follows zero-order kinetics at high therapeutic concentrations [2]. It does not sequester in skeletal muscle. **High-Yield NEET-PG Pearls:** * **Tissue Reservoirs:** * **Muscle:** Digoxin [1] * **Adipose Tissue:** Thiopental, Amiodarone * **Bone/Teeth:** Tetracyclines, Fluoride * **Retina:** Chloroquine (binds to melanin) * **Liver:** Chloroquine, Emetine * **Digoxin Monitoring:** Since Digoxin is sequestered in muscles, plasma levels do not reflect tissue levels immediately after administration. Blood for Therapeutic Drug Monitoring (TDM) should be drawn at least **6–8 hours** after the last dose to allow for distribution [4].

Question 324: Lorazepam can be safely used as a preanesthetic medication in a patient undergoing liver transplantation without fear of excessive CNS depression because the drug is:

A. excreted in unchanged form
B. actively secreted into the GI tract
C. conjugated extrahepatically (Correct Answer)
D. a selective anxiolytic devoid of CNS depressant actions

Explanation: **Explanation:** The correct answer is **C. conjugated extrahepatically.** **Concept:** Benzodiazepines (BZDs) are primarily metabolized in the liver via two pathways: 1. **Phase I (Oxidation):** Carried out by Cytochrome P450 enzymes. This process is significantly impaired in liver disease and often produces active metabolites with long half-lives (e.g., Diazepam). 2. **Phase II (Conjugation):** Glucuronidation converts the drug into inactive, water-soluble metabolites. Crucially, glucuronidation is relatively preserved in hepatic failure and can also occur **extrahepatically** (e.g., in the kidneys). Lorazepam, along with Oxazepam and Temazepam (remembered by the mnemonic **LOT**), undergoes direct Phase II conjugation without requiring Phase I oxidation. Therefore, even in a patient undergoing liver transplantation (severe hepatic impairment), Lorazepam does not accumulate to toxic levels, making it safer than other BZDs. **Analysis of Incorrect Options:** * **Option A:** Most BZDs are highly lipid-soluble and must be metabolized to water-soluble forms before excretion; they are not excreted unchanged. * **Option B:** BZDs are primarily excreted via the renal route after conjugation, not through active GI secretion. * **Option C:** Lorazepam is a potent CNS depressant. While it is used as an anxiolytic, it can cause significant sedation and respiratory depression at higher doses. **NEET-PG High-Yield Pearls:** * **LOT Drugs:** **L**orazepam, **O**xazepam, and **T**emazepam are the BZDs of choice in elderly patients and those with liver cirrhosis/failure. * **Midazolam:** Commonly used as a preanesthetic due to its short half-life and prominent **anterograde amnesia**, but it requires Phase I oxidation and is less safe in liver failure than Lorazepam. * **Flumazenil:** The specific antidote for BZD overdose (competitive antagonist at the GABA-A receptor).

Question 325: Urinary alkalinizing agents are administered in case of poisoning due to which type of drugs?

A. Weak bases
B. Weak acids (Correct Answer)
C. Strong bases
D. Strong acids

Explanation: **Explanation:** The principle behind urinary alkalinization is the **Ion Trapping Phenomenon**, which is governed by the Henderson-Hasselbalch equation. **1. Why Weak Acids are the Correct Answer:** Weakly acidic drugs (e.g., Salicylates, Phenobarbitone) exist in an equilibrium between ionized (charged) and unionized (uncharged) forms. In an alkaline medium (high pH), weak acids become **ionized**. Since ionized molecules are lipid-insoluble, they cannot diffuse back across the renal tubular epithelium into the bloodstream. This "traps" the drug in the tubular lumen, significantly increasing its renal clearance and excretion. **2. Why the Other Options are Incorrect:** * **Weak Bases:** In an alkaline urine, weak bases remain unionized (lipid-soluble), allowing them to be easily reabsorbed into the systemic circulation. To enhance the excretion of weak bases (e.g., Amphetamines), **urinary acidification** (using Ammonium Chloride) is required. * **Strong Acids/Bases:** These are already highly ionized at physiological pH levels. Their excretion is generally not significantly altered by minor shifts in urinary pH achieved through clinical alkalinization. **Clinical Pearls for NEET-PG:** * **Agent of Choice:** **Sodium Bicarbonate ($NaHCO_3$)** is the standard agent used to alkalinize urine (Target pH: 7.5–8.5). * **Classic Examples:** Forced alkaline diuresis is most commonly tested for **Salicylate (Aspirin)** and **Barbiturate** poisoning. * **Contraindication:** Do not alkalinize urine in patients with renal failure or congestive heart failure due to the risk of fluid and sodium overload. * **Mnemonic:** **"Like dissolves in Like"** (Unionized/Absorbed); **"Opposites Ionize"** (Ionized/Excreted). Acidic drug + Basic urine = Excretion.

Question 326: Detoxification of drugs is primarily controlled by which enzyme system?

A. Cytochrome
B. Cytochrome P450 (Correct Answer)
C. Cytochrome C
D. Cytochrome A

Explanation: **Explanation:** The detoxification of drugs (biotransformation) is primarily mediated by the **Cytochrome P450 (CYP450)** enzyme system. These are a superfamily of heme-containing enzymes located mainly in the smooth endoplasmic reticulum of hepatocytes. They catalyze **Phase I reactions**, primarily oxidation, which increase the polarity of lipophilic drugs to facilitate their excretion from the body. **Why the other options are incorrect:** * **Cytochrome:** This is a general term for a broad class of hemeproteins involved in electron transport. It is too non-specific to describe drug metabolism. * **Cytochrome C:** This is a specific component of the mitochondrial electron transport chain (ETC) essential for ATP production and apoptosis; it does not play a role in xenobiotic metabolism. * **Cytochrome A:** This is a component of Cytochrome c oxidase (Complex IV) in the mitochondrial respiratory chain, involved in the final step of electron transfer to oxygen. **High-Yield NEET-PG Pearls:** * **CYP3A4:** The most abundant isoform in the liver and responsible for metabolizing approximately 50% of all clinical drugs. * **CYP2D6:** Shows significant **genetic polymorphism**, affecting the metabolism of drugs like codeine (pro-drug activation) and metoprolol. * **Inducers vs. Inhibitors:** Knowledge of CYP inducers (e.g., Rifampicin, Phenytoin, Carbamazepine) and inhibitors (e.g., Ketoconazole, Erythromycin, Grapefruit juice) is crucial for identifying potential drug-drug interactions. * **Microsomal Enzymes:** CYP450 enzymes are "microsomal," meaning they are found in the microsomal fraction of liver homogenates (derived from the ER).

Question 327: The volume of plasma from which a substance is completely removed by filtration and secretion in the kidney is equal to which of the following?

A. Rate of elimination
B. Clearance (Correct Answer)
C. Volume of distribution
D. Bioavailability

Explanation: ### Explanation **1. Why the Correct Answer is Right:** **Clearance (CL)** is defined as the volume of plasma from which a drug is completely removed per unit of time (e.g., mL/min) [1]. In the context of the kidney, it represents the sum of glomerular filtration and tubular secretion, minus any tubular reabsorption [2]. It does not indicate the *amount* of drug removed, but rather the *volume of fluid* that is cleared of the drug. The formula is: $CL = \frac{\text{Rate of elimination}}{\text{Plasma concentration (C)}}$ [3] **2. Why the Incorrect Options are Wrong:** * **Rate of Elimination (A):** This refers to the actual mass or amount of drug (e.g., mg/hr) removed from the body per unit time [3]. Unlike clearance, the rate of elimination in first-order kinetics changes as the plasma concentration changes. * **Volume of Distribution (Vd) (C):** This is a theoretical volume that relates the total amount of drug in the body to its plasma concentration ($Vd = \frac{\text{Amount}}{\text{Concentration}}$). It indicates how extensively a drug distributes into extravascular tissues, not its removal rate. * **Bioavailability (D):** This is the fraction (F) of an administered dose that reaches the systemic circulation in an unchanged form. It is a measure of absorption and first-pass metabolism, not excretion. **3. NEET-PG High-Yield Clinical Pearls:** * **Renal Clearance Markers:** Inulin clearance is the gold standard for measuring GFR because it is filtered but neither secreted nor reabsorbed [2]. Creatinine clearance is used clinically to estimate GFR. * **Loading Dose vs. Maintenance Dose:** Clearance is the primary pharmacokinetic parameter used to calculate the **Maintenance Dose**. In contrast, Volume of Distribution (Vd) is used to calculate the **Loading Dose**. * **Zero-order vs. First-order:** For most drugs (First-order), clearance remains constant regardless of plasma concentration [1]. For drugs like Phenytoin or Alcohol (Zero-order), clearance decreases as the plasma concentration increases (saturation kinetics) [3].

Question 328: Which of the following drugs affect CYP 3A4 enzymes?

A. Fexofenadine
B. Phenytoin (Correct Answer)
C. Carbamazepine
D. Azithromycin

Explanation: **Explanation:** The Cytochrome P450 (CYP) enzyme system is the primary pathway for drug metabolism in the liver. **Phenytoin** is a potent **inducer** of the CYP 3A4 isoenzyme. By inducing these enzymes, phenytoin increases the metabolic rate of co-administered drugs (e.g., oral contraceptives, warfarin), leading to decreased therapeutic efficacy. **Analysis of Options:** * **Phenytoin (Correct):** A classic microsomal enzyme inducer. It increases the synthesis of CYP enzymes, specifically 3A4 and 2C9/2C19. * **Carbamazepine:** While Carbamazepine is also a potent CYP 3A4 inducer, in the context of standard NEET-PG questions where a single best answer is required and Phenytoin is listed, Phenytoin is often the prototypical example used. *Note: In many clinical scenarios, both B and C would be technically correct as they are both "Big Inducers."* * **Fexofenadine:** This is a second-generation antihistamine known for being a "non-sedating" metabolite of terfenadine. It does not significantly induce or inhibit CYP enzymes, making it safer regarding drug-drug interactions. * **Azithromycin:** Unlike other macrolides (Erythromycin, Clarithromycin), Azithromycin does **not** significantly inhibit CYP 3A4. This is a high-yield distinction often tested to differentiate it from its class members. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. * **Mnemonic for Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**erfenadine, **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**itrofurantoin, **K**etoconazole. * **Grapefruit juice** is a specific and potent inhibitor of intestinal CYP 3A4.

Question 329: Volume of distribution is NOT affected by all EXCEPT?

A. Binding to plasma protein (Correct Answer)
B. Drug clearance
C. Lipid insolubility
D. Absence of blood brain barrier

Explanation: **Explanation:** The question uses a double negative ("NOT affected by all EXCEPT"), which simplifies to: **"Which of the following factors affects the Volume of Distribution (Vd)?"** **1. Why Option A is Correct:** The **Volume of Distribution (Vd)** is a theoretical volume that relates the amount of drug in the body to its plasma concentration ($Vd = \text{Total amount of drug} / \text{Plasma concentration}$). * **Plasma Protein Binding:** Drugs that bind extensively to plasma proteins (like albumin) are "trapped" in the vascular compartment. This maintains a high plasma concentration, resulting in a **low Vd**. * Conversely, drugs that bind heavily to peripheral tissues (e.g., Digoxin) have a very **high Vd**. Therefore, protein binding is a primary determinant of Vd. **2. Why Other Options are Incorrect:** * **B. Drug Clearance:** Clearance refers to the *rate* at which a drug is removed from the body (volume per unit time). While Vd and Clearance both determine the **Half-life ($t_{1/2}$)**, clearance itself does not change the initial distribution volume of a drug. * **C. Lipid Insolubility:** This is a distractor. While lipid *solubility* increases Vd (by allowing drugs to cross membranes into tissues), lipid *insolubility* (water solubility) generally keeps drugs in the extracellular fluid, resulting in a lower Vd. However, the question asks for the factor that *directly* dictates distribution dynamics in the context of binding. * **D. Absence of Blood-Brain Barrier:** While the BBB limits distribution to the CNS, its absence is not a standard physiological parameter used to define Vd for most systemic drugs. **High-Yield Clinical Pearls for NEET-PG:** * **Low Vd (< 5L):** Drug is confined to plasma (e.g., Heparin, Warfarin). * **High Vd (> 15L):** Drug is sequestered in tissues (e.g., Digoxin, Chloroquine). * **Loading Dose Calculation:** $LD = Vd \times \text{Target Plasma Concentration}$. If a drug has a high Vd, a larger loading dose is required to saturate tissue sites. * **Hemodialysis:** Drugs with a **large Vd** cannot be efficiently removed by hemodialysis because most of the drug is outside the bloodstream.

Question 330: An elderly patient presents with myocardial infarction and a severe ventricular arrhythmia. The chosen antiarrhythmic drug has a narrow therapeutic window, with a minimum toxic plasma concentration 1.5 times the minimum therapeutic plasma concentration. The drug's half-life is 6 hours. It is crucial to maintain the plasma concentration above the minimum therapeutic level to prevent lethal arrhythmia. Which of the following dosing regimens is most appropriate?

A. Once daily
B. Twice daily
C. Four times daily
D. Constant intravenous infusion (Correct Answer)

Explanation: ### Explanation **1. Why Constant Intravenous Infusion is Correct:** The core concept here is the **Therapeutic Index (TI)** and **Plasma Concentration Fluctuations**. The drug has a very narrow therapeutic window (Toxic concentration is only 1.5x the Therapeutic concentration). In pharmacokinetics, intermittent dosing (oral or bolus) causes "peaks" and "troughs." If the peak-to-trough ratio exceeds the therapeutic window, the patient will either experience toxicity at the peak or sub-therapeutic levels (risk of lethal arrhythmia) at the trough. To maintain a **steady-state concentration ($C_{ss}$)** within a narrow range without fluctuations, a **constant intravenous infusion** is the gold standard. It ensures the plasma level remains precisely between the minimum effective and minimum toxic concentrations. **2. Why the Other Options are Incorrect:** * **A, B, and C (Once, Twice, or Four times daily):** These represent intermittent dosing. The drug's half-life is 6 hours. * If given **Once daily (24h)**: The drug undergoes 4 half-lives before the next dose, leading to massive fluctuations and prolonged sub-therapeutic periods. * Even **Four times daily (6h)**: Dosing at intervals equal to the half-life results in a 2-fold difference between peak and trough concentrations ($C_{max}/C_{min} = 2$). Since the toxic limit is only 1.5x the therapeutic limit, a 2-fold fluctuation would inevitably cause toxicity at the peak or treatment failure at the trough. **3. Clinical Pearls for NEET-PG:** * **Steady State:** It takes **4–5 half-lives** to reach steady-state plasma concentration. * **Narrow Therapeutic Index (NTI) Drugs:** Examples include Digoxin, Lithium, Warfarin, Theophylline, and Phenytoin. These require Therapeutic Drug Monitoring (TDM). * **Rule of Thumb:** If the dosing interval is shortened, fluctuations decrease. If the dosing interval is much longer than the half-life, the drug is effectively eliminated between doses. * **Loading Dose:** In emergencies (like MI with arrhythmia), a loading dose is often given before starting the infusion to reach the therapeutic target immediately.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free